AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VTVT · NASDAQ · Biotechnology

vTv Therapeutics (VTVT)

Develops oral small molecules for diabetes, centered on cadisegliatin alongside insulin.

$33.61

At close+1.66 (+5.20%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions44 holders · as of Jun 30, 2026	40.65%	1.61M shares
Insiders4 holders · as of Feb 18, 2026	28.88%	1.14M shares
Strategic holders1 holder · as of Dec 6, 2024	5.23%	206.8K shares
Otherremainder	25.24%	998.0K shares

3.95M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Two share counts disagree (3.95M in the company's Sep 3, 2026 report, 2.62M elsewhere); stakes use the report.

This company has 2 share classes; every stake here is a share of the whole company.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Srinivas Akkaraju¹Insiderdirector	10.22%	403,942 A	13Dfiled Dec 9, 2025 ↗
Paul J. SekhriInsiderdirector, officer: Pres, CEO and Exec Chairperson	9.92%	392,212 A	Form 4filed Feb 18, 2026 ↗
Invus Public Equities, L.P.Insider	8.75%	345,926	13Gfiled Nov 12, 2025 ↗
Samsara Biocapital, LLCInstitution	7.55%	298,496 A	13Fas of Jun 30, 2026
Millennium Management LLCInstitution	6.83%	269,874 A	13Fas of Jun 30, 2026
FMR LLCInstitution	6.59%	260,391 A	13Fas of Jun 30, 2026
Samsara BioCapital GP, LLCStrategic10 percent owner	5.23%	206,784 A	Form 4filed Dec 6, 2024 ↗
Siren, L.L.C.Institution	4.12%	163,000 A	13Fas of Jun 30, 2026
Baker Bros. Advisors LPInstitution	3.75%	148,314 A	13Fas of Jun 30, 2026
Vanguard Capital Management LLCInstitution	2.39%	94,463 A	13Fas of Jun 30, 2026
Trails Edge Capital Partners, LPInstitution	2.15%	85,192 A	13Fas of Jun 30, 2026
Aisling Capital Management LPInstitution	1.26%	50,000 A	13Fas of Jun 30, 2026
Marshall Wace, LLPInstitution	1.00%	39,560 A	13Fas of Jun 30, 2026
Geode Capital Management, LLCInstitution	0.82%	32,470 A	13Fas of Jun 30, 2026
Renaissance Technologies LLCInstitution	0.44%	17,454 A	13Fas of Jun 30, 2026
Vanguard Fiduciary Trust CoInstitution	0.41%	16,239 A	13Fas of Jun 30, 2026
BlackRock, Inc.Institution	0.37%	14,731 A	13Fas of Jun 30, 2026
Jane Street Group, LLCInstitution	0.35%	13,703 A	13Fas of Jun 30, 2026
State Street CorpInstitution	0.31%	12,266 A	13Fas of Jun 30, 2026
Two Sigma Investments, LPInstitution	0.29%	11,486 A	13Fas of Jun 30, 2026
Verdad Advisers, LPInstitution	0.23%	8,996 A	13Fas of Jun 30, 2026
Integrated Quantitative Investments LLCInstitution	0.21%	8,210 A	13Fas of Jun 30, 2026
Susquehanna International Group, LLPInstitution	0.20%	8,023 A	13Fas of Jun 30, 2026
Quadrature Capital LtdInstitution	0.16%	6,305 A	13Fas of Jun 30, 2026
Trexquant Investment LPInstitution	0.16%	6,240 A	13Fas of Jun 30, 2026

Srinivas Akkaraju's transaction reports restate only vehicles that traded; the 2025 ownership statement (403.9K) is used instead.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Jun 30, 2026

44 holders · 1.61M shares · 17 new positions · 23 increased · 7 reduced · 8 closed

Holder	Shares	% of company	Chg q/q	Filed
Samsara Biocapital, LLC	298.5K	7.55%	0	Aug 14, 2026
Millennium Management LLC	269.9K	6.83%	+63.6K	Aug 14, 2026
FMR LLC	260.4K	6.59%	0	Aug 13, 2026
Siren, L.L.C.	163.0K	4.12%	0	Aug 13, 2026
Baker Bros. Advisors LP	148.3K	3.75%	0	Aug 14, 2026
Vanguard Capital Management LLC	94.5K	2.39%	−14.5K	Aug 13, 2026
Trails Edge Capital Partners, LP	85.2K	2.15%	−54.4K	Aug 14, 2026
Aisling Capital Management LP	50.0K	1.26%	+50.0Knew	Aug 13, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Srinivas Akkarajuincl. Samsara BioCapital, L.P., Samsara Opportunity Fund GP, LLC +2 more	9.90%	403.9K	13D	Dec 9, 2025 ↗
Trails Edge Capital Partners, LP	9.90%	340.5K	13G	Sep 8, 2025 ↗
Invus Public Equities, L.P.	8.40%	345.9K	13G	Nov 12, 2025 ↗
FMR LLCincl. Abigail P. Johnson	7.32%	178.2K		Nov 12, 2024 ↗
Integrated Core Strategies (US) LLC	5.00%	198.7K	13G	Apr 16, 2026 ↗
Millennium Management LLC	5.00%	198.2K	13G	Mar 27, 2026 ↗

vTv Therapeutics (VTVT)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F, as of Jun 30, 2026

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures